Newest Cause of Depression? Our Solar System
November 10, 2026– Robert Carter
The Associated Press has been running an article this week by its veteran medical writer Carla K. Johnson about the “millions of people” who can be diagnosed with Seasonal Affective Disorder. In the autumn when the sun sets earlier, these poor folks suffer from episodes of depression which “can include persistent feelings of hopelessness or pessimism and difficulty concentrating, remembering, or making decisions.”
Guess we’ll need Big Pharma to drug these folks, too, to take them out of their misery, huh?
And that’s exactly what the article suggests. “Antidepressant medications are a first-line treatment for SAD,” the Johnson writes. The National Institute of Health, champion of DSM diagnoses, notes that SAD affects far more women than men (of course), but no specific biomarker has been found (of course) which causes this mental disorder.
Apparently artificial bright light therapy can help some with this disease that was “discovered” in 1984 by Dr. Norman Rosenthal, a researcher at the National Institute of Health, who then coined the term SAD. Since then significant research has been done on SAD at Yale Winter Depression Research Clinic (yes, that lab actually exists, we’re not kidding) and at the University of Pittsburgh, probably both funded by healthy grants from the government or Big Pharma.
No research is mentioned in the article about those unlucky sods who live in northern Alaska communities like Barrow where the sun does not appear at all for 65 days every winter. If SAD is that devastatingly depressive, perhaps there’s no one left there to research as they’ve all committed suicide by spring.
With such a natural source of depression as the solar cycle of earth, perhaps a more natural source of medication – like psychedelics — will be recommended for treatment by Big Pharma instead of a mere prescription for Zoloft, Celexa or Paxil.
AP writer Johnson has reported on that, as well. She wrote an article for Fortune in 2023 about Australia’s recent approval of psychiatrists to write prescriptions for psilocybin. She also notes the “wider cultural acceptance” of magic mushroom therapy in the U.S. In another 2025 article for NPR she wrote that microdosing psilocybin or LSD is gaining popularity “to reduce anxiety, stress and depression.”
Johnson included in the article coverage of Casey Means, a prospective U.S. Commissioner of Food and Drugs, and Means’ public encouragement of further research into psychedelic therapy, “one of the most meaningful experiences of life for some people, as they have been for me.” Johnson also included a quote in t her article by Calley Means, government advisor and brother of Casey, that his taking psilocybin was “the single most meaningful experience of my life.”
To her credit, Johnson also reports that Calley had sold all his 401k’s to buy stocks in two companies developing and researching psychedelics. Go, Big Pharma.
Wittingly or unwittingly, Carla Johnson is paving the way for public acceptance of Big Pharma’s shifting to a more natural — but surely no less profitable — mental disorder therapy than today’s synthetic antidepressants.
Will Big Pharma’s next big marketing campaign then be founded on the slogan “Turn on, tune in, drop out”?
Oh, no, wait. That’s been done before.
Comments are moderated. You must be logged in to comment. Please keep it civil